Insmed (NASDAQ:INSM) Price Target Raised to $237.00 at Barclays

Insmed (NASDAQ:INSM) had its target price raised by Barclays from $231.00 to $237.00 in a report released on Wednesday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently commented on the stock. Stifel Nicolaus boosted their target price on shares of Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Rothschild & Co Redburn set a $263.00 price objective on shares of Insmed in a research note on Thursday, December 4th. Roth Mkm upgraded shares of Insmed to a “strong-buy” rating in a research report on Friday, January 23rd. Royal Bank Of Canada upped their target price on Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Finally, Mizuho raised their target price on Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $212.67.

Insmed Stock Performance

INSM opened at $164.86 on Wednesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. Insmed has a 52-week low of $60.40 and a 52-week high of $212.75. The firm has a market cap of $35.54 billion, a P/E ratio of -25.72 and a beta of 1.10. The business’s fifty day moving average is $150.14 and its 200-day moving average is $166.41.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The company had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The firm’s revenue for the quarter was up 152.6% compared to the same quarter last year. During the same period last year, the firm earned ($1.32) EPS. Sell-side analysts expect that Insmed will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 19,215 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the sale, the chief executive officer owned 306,891 shares of the company’s stock, valued at approximately $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the transaction, the insider owned 41,754 shares of the company’s stock, valued at $7,315,300.80. This trade represents a 67.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 189,651 shares of company stock valued at $31,533,654. 3.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Insmed

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Insmed by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after purchasing an additional 1,140,524 shares during the last quarter. Darwin Global Management Ltd. raised its stake in Insmed by 2.3% during the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after buying an additional 475,832 shares during the last quarter. Capital International Investors lifted its holdings in Insmed by 1.0% in the third quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after buying an additional 74,994 shares during the period. State Street Corp lifted its holdings in Insmed by 30.6% in the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after buying an additional 1,217,390 shares during the period. Finally, Artisan Partners Limited Partnership boosted its position in Insmed by 49.0% during the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after acquiring an additional 1,623,342 shares during the last quarter.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.